

Fresenius Kabi USA

NDC	DRUG PROD DESC
63323-0685-17	Posaconazole Intravenous Solution 300 MG/16.7ML

INTRODUCED TO MARKET DATE	WAC AT INTRODUCTION
1/16/2024	15910.00

MARKETING PRICING PLAN	MARKETING PRICING NONPUBLIC
Fresenius Kabi has not spent any money directly related to advertising Posaconazole. At this time we do not plan on doing any direct to consumer advertising. Launching a generic product that offers more than 49% (\$260.45) savings to market leader at launch PAR.	Y

ESTIMATED PATIENTS	BREAKTHROUGH THERAPY INDICATOR	PRIORITY REVIEW INDICATOR
500000.00	N	N

ACQUISITION DATE	ACQUISITION PRICE	ACQUISITION PRICE NONPUBLIC
N/A	N/A	N/A

ACQUISITION PRICE COMMENT	GENERAL COMMENTS
N/A	WAC is based off 30 day course of therapy.